Can a smart glucose monitor keep blood sugar in check after hospital leave?
NCT ID NCT07414277
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two ways of tracking blood sugar in people with type 2 diabetes who use insulin after leaving the hospital. One group uses a continuous glucose monitor (CGM) that shows real-time levels and trends, while the other group uses traditional fingerstick tests. The goal is to see if CGM leads to better blood sugar control over 12 weeks, with follow-up at 24 weeks. 160 adults aged 18–80 with type 2 diabetes and an HbA1c between 8% and 13% are being recruited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Real-Time Continuous Glucose Monitoring (RT-CGM) device
- What this could lead to
- If it works, this could show that using a continuous glucose monitor helps people with type 2 diabetes manage their blood sugar better after leaving the hospital.
- What could go wrong
- This is a relatively small, early-stage trial (160 people) comparing two monitoring methods, not testing a new drug or cure. The results may not apply to all patients, and the device itself does not treat diabetes—it only tracks glucose levels.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18 to 80 years (inclusive). 2. Confirmed diagnosis of type 2 diabetes mellitus (T2DM). 3. HbA1c between 8.0% and 13.0% (inclusive) within the last 1 month prior to screening/enrollment. 4. Planned to receive insulin therapy for at least 6 months after hospital discharge, as assessed/confirmed by the treating physician (principal physician). Exclusion Criteria: 1. Current use of a real-time continuous glucose monitoring (RT-CGM) device, or use within the 3 months prior to enrollment. 2. Severe skin disease at the sensor insertion site, or allergy to adhesive tape/adhesives. 3. Pregnant women; positive pregnancy test at screening; or planning pregnancy during the study period. 4. Currently participating in, or planning to participate in, another clinical trial. 5. Current use of oral corticosteroid therapy, or anticipated use during the trial period. 6. Severe liver disease, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 times the upper limit of normal (ULN). 7. Severe renal impairment or end-stage renal disease, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m². 8. Any condition that, in the investigator's opinion, makes the participant unsuitable for the trial, for example: history of ocular trauma or other diagnosed eye diseases causing visual impairment; unwillingness to participate or inability to adequately understand/comply due to speech/language impairment; or presence of psychiatric disorders.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus (T2DM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shanghai 6th People's Hospital
RECRUITINGShanghai, China
-
Shanghai 7th People's Hospital
RECRUITINGShanghai, 200137, China
-
Shanghai Fengxian District Central Hospital
RECRUITINGShanghai, China
-
Shanghai General Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four pills, one goal: can a new combo tame type 2 diabetes?
- Can banding the gut tame type 2 diabetes?
- Can QR codes and videos teach better foot care?
- Can a new injection help tackle obesity? a trial puts MWN105 to the test
- Can when you eat change how a diabetes drug works?
- Can a new daily pill outperform semaglutide for diabetes?